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“You matter because you are you. You matter to the last moment of your life, and we will 
do all we can to help you not only to die peacefully, but also to live until you die.”  
Dame Cicely Saunders, St. Christopher's Hospice 
1. Introduction 
The doctor-clown Patch Adams argued that our health care system should not treat the 
disease, but the patient, in an approach "patient-centered" rather than “disease-centered”. 
Palliative care is a holistic, patient-centered, and culturally sensitive approach to care. 
According to the Nobel Prize winner Rita Levi Montalcini, “it’s better to add life to days, 
rather then days to life”. For those who are dying a good quality of their last days of life is 
more important rather than prolong unnecessarily the days of the agony. Palliative care 
focuses on relieving suffering and achieving the best possible quality of life for patients and 
their family caregivers. 
Palliative medicine (from the Latin word "pallium" for mantle, as a synonym of protection) 
takes care of the patients (and their boundary) rather than the disease(s) that afflicts them.  
Palliative care involves not only the patients themselves, but also their families and 
communities. In practice, palliative care integrates two essential components of care. One is 
the control of symptoms and pain, the other are the interventions to meet the psychological, 
social, and spiritual needs of the patient and the family. The palliative care framework calls 
for varied combinations of these two components to be provided over the full course of the 
illness, from diagnosis to death, and through the bereavement of family members. 
The National Consensus Guidelines for Palliative Care (2011) state the goals of palliative care 
are to prevent and relieve suffering and to support the best possible quality of life for patients 
and their families, regardless of the stage of the disease or the need for other therapies.  
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The role of the General Practitioner (GP) is central to community palliative care. Good 
liaison between the different professionals involved in a patient's care is extremely 
important for patients in palliative care. In cases where GPs have previously been 
dissatisfied with palliative services, this may be seen as a barrier to referral when caring for 
other patients (Bajwah, 2008). With a GP's longitudinal knowledge of patients, and the 
likelihood that they have shared the journey of the final illness with the patient, it should be 
beyond dispute that there should be a central role for general practice in palliative care. 
Physicians must adopt a vision that takes into account the effects that diseases are having 
not just on patients but also on patients’ caregivers and loved ones, a systemic vision. 
(Emanuel et al, 2011).  
The essence of the doctor–patient relationship makes family physicians ideally suited to 
provide care palliative and end-of-life. Cassell, (1982), has defined that this relationship is 
the very means to help relieve suffering. 
In order to develop the wide term of palliative care, we would like to consider both advance 
care planning, aid with decision making and clinical care management. 
2. Palliative care in general practice: Why is it so important?  
Mr Ralph Smith is a man 74 years old who has suffered from a pulmonary cancer for 
about 15 months, treated with chemotherapy and radiotherapy on the chest. He lives 
with his wife (72 y.o.), hemiplegic for an ictus, and a daughter (40 y.o.), who works as a 
primary teacher. Recently he has developed a metastatic localization in the lumbar spine 
with increasing pain, severe limitation to movement and urinary retention. The general 
conditions are quite compromised (Karnofsky Index < 40) with a very poor prognosis 
(less than 3 months). Ralph refused the antalgic radiotherapy on the lumbar spine 
proposed by the oncologist. His family doctor proposed him a palliative care program by 
the Home Palliative Care Team. 
Palliative care, with its focus on management of symptoms, psychosocial support, and 
assistance with decision making, has the potential to improve the quality of care and reduce 
the use of medical services. However, palliative care has traditionally been delivered late in 
the course of disease to patients who are hospitalized in specialized inpatient units or as a 
consultative service for patients with uncontrolled symptoms. Previous studies (Morita et al, 
2005; Zimmermann et al, 2008) have suggested that late referrals to palliative care are 
inadequate to alter the quality and delivery of care provided to patients with cancer. To 
have a meaningful effect on patients’ quality of life and end-of-life care, palliative care 
services must be provided earlier in the course of the disease (Temel et al, 2010). 
To date, evidence supporting a benefit of palliative care is sparse, with most studies having 
notable methodologic weaknesses, especially with respect to quality-of-life outcomes 
(Zimmermann et al, 2008). One study showed that Project ENABLE (Educate, Nurture, 
Advise, Before Life Ends), a telephone-based, psychoeducational program for patients with 
advanced cancer, significantly improved both quality of life and mood (Bakitas et al, 2009) . 
Another recent study (Temel et al, 2010) showed that early outpatient palliative care for 
patients with advanced cancer can alter the use of health care services, including care at the 
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end-of-life. Early introduction of palliative care led to less aggressive end-of-life care and 
showed greater documentation of resuscitation preferences in the outpatient electronic 
medical record, an essential step in clarifying and ensuring respect for patients’ wishes 
about their care at the end-of-life (Walling et al, 2008). Less aggressive end-of-life care did 
not adversely affect survival.  
Given the trends toward aggressive and costly care near the end-of-life among patients with 
cancer, timely introduction of palliative care may serve to mitigate unnecessary and 
burdensome personal and societal costs (Emanuel et al, 2002; Earle et al, 2008; Sullivan et al, 
2011). 
Morrison and Meier (2004) articulate five broad areas of skills that form the core of palliative 
medicine: physician–patient communication; assessment and treatment of symptoms; 
psychosocial, spiritual, and bereavement care; coordination of care. This involves defining 
practice standards, responsibility for educational development and implementation, 
research in partnership with the academy, and program and systems needs. 
In palliative care, the dying is seen as having an important role, complete with tasks and 
expectations, that is different from the sick role when recovery is expectable (Davies, 2009). 
The goal is not to prolong or shorten life; rather, the process of dying is to be freed of as 
much unnecessary suffering as possible. The inevitable dimensions of suffering that 
accompany dying and death can be soothed by finding meaning and purpose in the life 
lived and enhancing quality of life and quality of the dying process (Emanuel et al, 2011). 
Palliative care is a paradigm of excellence for the generalist. The specific nature of palliative 
care allows GPs to showcase the strength of a generalist approach. This ‘excellence’ 
manifests as a creative tension between evidence-based biomedical care, a patient-centered 
approach and the more traditional role of ‘healer’. GPs think and reflect around patient 
stories, rather than the abstraction of data to achieve best practice care (Eti & Heidelbaugh, 
2011).  
Patients repeatedly emphasize the importance of the role of a family physician with whom 
they have had close ties over the years, and for this role to continue through the palliative 
stages of life (Emanuel et al, 2007). Physicians must adopt a systemic vision, a vision that 
takes into account the effects that diseases are having not just on patients but also on 
patients’ caregivers and loved ones (Emanuel et al, 2011). The family physician is also well 
positioned to address the concerns of the patient's loved ones and assist in coping with grief, 
as these persons are often patients in the physicians’ practice (Lehman & Daneault, 2006).  
An in-depth understanding of suffering in those who are seriously ill, and responding to it, 
is a fundamental role of primary care. Family physicians have the capacity to stay available 
and involved in care in a way that is reassuring to patients and alleviates patient suffering. 
The primary care physicians often must deliver the bad news, discuss the prognosis, and 
make appropriate referrals. When delivering bad news, it is important to prioritize the key 
points that the patient should retain. Physicians should assess the patient's emotional state, 
readiness to engage in the discussion, and level of understanding about the condition. When 
discussing prognosis, physicians should be sensitive to variations in how much information 
patients want to know. The challenge for physicians is to communicate prognosis accurately 
without giving false hope. Physicians also must be aware of how cultural factors may affect 
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end-of-life discussions. Sensitivity to a patient's cultural and individual preferences will 
help the physician avoid stereotyping and making incorrect assumptions.  
Primary care physicians have the opportunity to maintain long-term, trusting relationships 
with patients and are well positioned to discuss difficult issues such as incurable disease or 
terminal illness (Ngo-Metzger et al, 2008). 
A good primary palliative care is essential, as it allows patients to remain at home as long as 
possible. It is known that most patients wish to do so and would eventually prefer to die at 
home among family and friends (Marieke et al, 2007). 
A systematic review of studies (Daneaul & Dion, 2004) found that, overall, the majority of 
the general population as well as patients and caregivers would prefer to die at home, but 
the findings varied considerably by study, with the percentage of people preferring to die at 
home ranging from 25% to 100%.  
Several studies have repeatedly shown that many terminally ill patients prefer the option of 
a death at home (Watson, 2008). 
However there can be profound shifts in patient and caregiver preference for location of 
death as the illness progresses. Hinton (1994) found that the preference for a home death 
changed from 90% initially to 50% as death approached (Higginson & Sen-Gupta, 2000). 
Most GPs testify to this being one of the more difficult, but most satisfying, parts of their job. 
Survey results of different populations vary considerably with regard to preference for 
home as the location of death (Davies & Higginson, 2004). 
Helping patients die with dignity and with minimal distress has been one of the most 
fundamental aspects of medicine, and over the past 50 years specialistic palliative care 
services have increasingly worked with general practice to develop more advanced 
knowledge and skill than ever before.  
The European Association of Palliative Care conducted a study, begun in 2003, that 
evaluated the situation of palliative care through Europe. A report with quantitative and 
qualitative data was prepared for 43/52 participating countries. In table 1 different 
organizational models, (Hospital based, Hospice and Home care) in European countries are 
shown. Iceland is at the first place with a rate of 20 service for million inhabitants, equally 
distributed as a hospital model or home care assistance. 
Different models of service delivery have been developed and implemented throughout the 
countries of Europe. UK, Germany, Austria and Belgium have a well-developed and 
extensive network of hospices. Day Centres are a development that is characteristic of the 
UK with hundreds of these services currently in operation. The number of beds per million 
inhabitants ranges between 45-75 beds in the most advanced European countries, to only a 
few beds in others. The model for mobile teams or hospital support teams has been adopted 
in a number of countries, most notably in France (Centeno, 2007).  
Italy and many other countries as Hungary, Bulgaria, Poland, Slovenia, etc. have preferably 
developed a Home care model based on a multidisciplinary team which include General 
Practitioners. 
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Rank Country 
Total  
Services/ 
Million 
Inhabitants 
Hospital  
Support  
and Unit 
/Hospice 
Home care 
First Opioid 
used 
1 Iceland 20,3 50 % 50 % Morphine 
2 United Kingdom 16,0 61 % 39% Morphine 
3 Belgium 11,6 88% 12% Fentanyl 
4 Poland 9,5 36% 64% Morphine 
5 Ireland 8,9 61% 39% Morphine 
6 Luxemburg 8,8 50% 50% Fentanyl 
7 Netherlands 8,5 100% 0% NA 
8 Armenia 8,1 67% 33% Morphine 
9 France 7,8 82% 18% NA 
10 Norway 6,7 97% 3% Morphine 
11 Austria 6,4 67% 33% Fentanyl 
12 Spain 6,0 47% 53% Fentanyl 
13 Bulgaria 5,5 39% 61% Morphine 
14 Switzerland 5,1 63% 37% NA 
15 Finland 5,0 62% 38% Morphine 
16 Hungary 4,3 35% 65% Morphine 
17 Germany 3,9 91% 9% Morphine 
18 Italy 3,8 36% 64% Fentanyl 
19 Israel 3,7 46% 54% Oxycodone 
20 Slovenia 3,6 29% 71% Morphine 
21 Moldova 3,3 15% 85% Morphine 
22 Denmark 3,3 72% 28% Morphine 
23 Cyprus 3,2 50% 50% Morphine 
24 Macedonia 2,9 67% 33% Morphine 
25 Malta 2,6 100% 0% Morphine 
NA: not available 
Table 1. Palliative Care Specific Resources in Europe (Modified from EAPC, 2006) 
However palliative care is still perceived by most physicians and patients as a waiver to care 
and a sentence to death. For these main reasons negative myths about palliative care have 
developed (Table 2). 
These often are common barriers to the adoption and effectiveness of palliation in Primary 
Care. Health Systems should invest in improving the quality of Palliative Home Care to get 
an assistance really focused on the needs of the patient and his boundary. And it is 
fundamental to invest on physicians’ communication skills. 
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Negative Myths Palliative Care (PC) opportunities 
PC means that 
doctors have 
given up on a 
patient. 
When PC is proposed, it means that the healthcare team has realized that 
the disease is not curable and that death can’t be avoided: PC offers the 
chance to live out the remaining days as comfortably as they can be, with 
the care of experts in end-of-life care. 
PC means no 
more treatment. 
When a PC team takes over the care of a patient, treatment doesn’t 
automatically stop. Treatment and therapies can continue, but they have 
a different goal.  
PC is only for 
people with 
cancer. 
PC is offered to anyone with an end-stage of a chronic or terminal illness. 
Many people who receive PC can have AIDS, heart disease, COPD, 
multiple sclerosis, muscular dystrophy, and many other fatal illnesses. 
PC is only for 
old people. 
Many children are diagnosed with terminal illnesses. They may be born 
with a birth defect, such as a heart defect, or a disease that will cause 
them to die as a child or they may develop a terminal illness later on in 
their childhood.  
PC means the 
patient is very 
close to death. 
When someone is transferred to the PC team, they may die within days or 
weeks, or they may live for considerably longer. PC isn’t offered 
according to the amount of time left. 
In PC the use of 
narcotics or 
opioids is a type 
of euthanasia. 
PC is not euthanasia. If the disease cause severe pain, the use of narcotics 
or opioids is useful to control the pain, but only if patient needs it and 
only at the dosages he needs it. The goal of PC isn’t to help the patient to 
die, but, on the contrary, to make him as comfortable as possible during 
the end-of-life period. 
PC can be given 
only in the 
hospital. 
PC services are offered in many communities. Care at end-of-life can be 
given in a hospital, stand-alone residence, or at home, depending on the 
resources available. 
PC reduce the 
family role. 
One of the benefits of PC is that it’s not only for the dying person. The PC 
team cares for the dying patient and his or her family and friends. The 
care at the end-of-life isn’t just about physical comfort, but it’s about 
emotional and psychological support for everyone who loves and is part 
of the life of the dying patient. 
PC reduce the 
auto-control of 
the patient. 
PC is a specialty in medicine. A patient in PC is consulted and is part of the 
team for as long as him or her is able to be (see also the paragraph on ACP). 
Table 2. Negative Myths of Palliative Care (PC) 
3. Doctor–patient relationship and patient-centered communication 
Mrs White Claire, a woman 40 years old, with two adolescent sons, is affected with a breast cancer 
with multiple liver, bones and brain metastases. Her mother died at 33 for breast cancer. She is 
currently receiving home care with opioids for bone pain. Her husband, John, requires to their GP 
a hospice admission for the appearance of a deep venous thrombosis in the right leg. At the 
admission the leg is edematous but not sore. The hospice doctor says to John that the general 
conditions are very compromised and the Claire prognosis is very poor (few days). He proposes not 
him initiate therapy with low molecular weight heparin, but to provide only supportive therapy. 
John is distressed and confused, he would like to counsel with their family doctor. 
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The patient–doctor relationship is an important concept in health care, especially in primary 
care. One of the main competences required to the General Practitioner (GP) in the field of 
palliative care is to establish a good relationship both with the patient, the family and the 
other health care professionals engaged in the care process. In order to provide high quality 
assistance, effective communication between patients and health care providers is an 
essential element. 
The clinicians need establish a therapeutic relationship based on trust and mutual respect 
with patients who often access a great deal of medical information, come from culturally 
diverse, have varying levels of social support, and confront the existential and spiritual 
aspects of dying, all while trying to access complicated health care systems (Foley & 
Gelband, 2001; Hewitt & Simone, 1999). 
The primary care physicians form the backbone of an integrated team by providing an 
unbiased medical perspective and continuity during a stressful disease course, supporting 
patients and their families through emotional ups and downs, negotiating or mediating 
decisions, monitoring for complications, and providing perspective on the illness (Parker et 
al, 2001). 
Despite around the 50-90% of the patients want to be informed about the diagnosis, the 
prognosis, the medical treatments and the side effects, even though it is a diagnosis of 
terminal phase, a relevant number of physician tends to hide unpleasant truths. In fact, 
patients affected by neoplasia with higher probabilities of being cured are usually informed 
more correctly and completely than patients affected by advanced disease (D’Errico & 
Valori, 2011). 
When a patient and his/her physician enter into end-of-life discussions, each brings 
individual cultural backgrounds and values, which influence the discussions. Although 
understanding cultural norms is important, physicians must be careful to avoid stereotyping 
patients based on their culture (Kagawa- Singer et al, 2001).  
The stress of disease and its treatment are often associated with intense negative emotions: 
sadness, fear, and anger. Though physicians often cannot “fix” the causes of these emotions, 
empirical studies indicate that providing emotional support ameliorates distress. Patients 
feel emotionally supported when their doctor shows care for them as a person, by spending 
enough time with them, allowing them to ask questions, and listening to their concerns 
(Wenrich et al, 2001). 
The physicians should assess how much information to provide using patient-centered 
communication. After assessing the patient’s readiness to receive prognostic information, 
the physician should focus on communicating the prognosis without giving false hope (Back 
et al, 2003). Though many clinicians equate honesty about a poor prognosis with destroying 
hope, healthy coping continually generates hope, even in difficult life situations. Even under 
situations of severe stress, positive emotions are prominent, and are an integral part of the 
coping process (Meier et al, 2001).  
An American study described patients’ hopes for a good death: freedom from pain and 
other symptoms, clear decision making, preparation for death, having a sense of completion, 
contributing to others, affirmation of the whole person, being at peace with God, being in 
the presence of family, being kept clean, and trusting one’s physician (Steinhauser et al, 
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2000). Maintaining hope is essential to patients and their families at the end-of-life (Clayton 
et al, 2005; Shiozaki et al, 2005). 
Retrospective studies (Ptacek et al, 2001; Salander, 2002; Wenrich et al, 2001) identified what 
patients want when hearing bad news. They prefer to have: bad news discussed in person, 
and in a private, quiet place; a physician who is able to communicate their diagnosis, 
prognosis, and treatment options clearly; full attention of the physician; time to ask 
questions; and to be given informations about how the diagnosis will affect their life (Back et 
al, 2008). 
The Evidence-based recommendations and the best practices on the communication of bad 
news are summarized in box 1: 
 Find a comfortable and private place to talk; 
 Ask whether the patient would like to have others present; 
 Minimize interruptions; 
 Assess the patient’s understanding of the situation; 
 Let the patient know explicitly that bad news is forthcoming; 
 Provide information honestly and in simple language; 
 Give time for questions; 
 Encourage patient to express emotions and respond empathically; 
 Check understanding; 
 Arrange a clear follow-up plan. 
Box 1. Best practice for communicating bad news (adapted from Back et al, 2008). 
The goals of care change as the disease progresses. At each stage, the physician should help 
the patient create realistic, achievable goals and hopes. Focusing on stage-specific goals and 
hopes can prevent over- and under-treatment while relieving the patient’s psychological 
distress (Block, 2006). 
Breaking bad news, particularly discussing prognosis, requires a combination of disease-
specific biomedical knowledge and excellent communication skills (Back & Arnold, 2006). 
Therefore, recommendations have been developed to help physicians appropriately deliver 
bad news, as reported in box 2: 
 It is important for physicians to assess the patient’s level of understanding about the 
disease and expectations for the future. 
 It is important for the physician to assess how much information the patient wants to 
know and to tailor the discussion appropriately. 
 The primary care physician should remain involved with patient care during the 
early, middle, and late stages of disease. 
 Physicians should avoid phrases and words that can be misconstrued by the patient 
and lead to negative interpretations such as abandonment and failure. 
 During end-of-life communication, physicians should assess and be sensitive to the 
patient’s cultural and individual preferences. 
Box 2. How to communicate bad news: recommendations for physicians (adapted from 
Ngo-Metzger et al, 2008) 
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Frequently, preparing the caregivers for the patient’s death is not a main focus of 
communication (Rabow et al, 2004). Usually the family of a terminally-ill patient prefers that 
diagnosis is hidden to its loved one. This behaviour can be seen as a psychological defense 
system through which the patient’s relatives face their own anxiety towards death. That is 
why the GP should also help the family members to understand what are the advantages of 
a frankly based relationship and what are the risks of a reticent and not honest relationship 
(D’Errico & Valori, 2011). 
Observational studies (Steinhauser et al, 2001; Hebert et al, 2006) suggest that inadequate 
information and unpredictable situations might contribute to caregiver uncertainty, which is 
associated with poorer health outcomes for the caregiver himself. On the contrary, other 
studies demonstrate that when the caregivers perceive that their questions have been 
answered, they experience fewer depressive symptoms, fewer economic and other burdens, 
and improve their satisfaction and quality of life (Valdimarsdottir et al, 2004). 
Knowledge about factors that hinder or facilitate the communication between GPs and 
patients in palliative care is needed in order to improve the quality of the palliative care 
itself and the life quality of the patients (Slort et al, 2011).  
The most frequently reported barriers for GP–patient communication are: 
 the GPs’ lack of time; 
 the patients’ ambivalence or unwillingness to know about the prognosis;  
 the GPs not talking honestly about the diagnosis or prognosis.  
The most frequently reported facilitating factors are: 
 the availability of the GPs, 
 longstanding GPs–patient relationships, 
 GPs showing commitment, being open and allowing any topic to be discussed, 
 being honest and friendly, 
 listening actively and taking patients seriously, 
 taking the initiative to talk about end-of-life issues, 
 not withholding information, 
 negotiating palliative care options,  
 being willing to talk about the diagnosis and prognosis, preparation for death, the 
patient’s psychological, social and spiritual issues and the patient’s end-of-life 
preferences. 
In conclusion give dignity, space and attention to the communication are essential steps that 
need to be undertaken by a GP that recognizes a correct relationship with the patient as one 
of his main means of care and essential for a better advance care planning. 
4. Advance care planning  
Advance care planning (ACP) is a process that can support individual autonomy with 
respect to health care choices throughout the course of a life-threatening illness and at the 
end-of-life. Advance directives (ADs) are documents enabling capable individuals to plan 
for care in the case of their own incapacity. 
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The Institute of Medicine (cited by Emanuel et al, 2011) defines ACP as “not only the 
preparation of legal documents but also discussions with family members and physicians 
about what the future may hold for people with serious illnesses, how patients and families 
want their beliefs and preferences to guide decisions (including decisions should sudden 
and unexpected critical medical problems arise), and what steps could alleviate concerns 
related to finances, family matters, spiritual questions, and other issues that trouble 
seriously ill or dying patients and their families”.  
As such, ACP is a process not a single event with the goal of learning about both what 
patients want and what they do not want for themselves in the future. 
ACP includes (National Hospice and Palliative Care Organization, 2011): 
 Getting information on the types of life-sustaining treatments that are available; 
 Deciding what types of treatment one would or would not want should one be 
diagnosed with a life-limiting illness; 
 Sharing personal values with loved ones; 
 Completing advance directives to put into writing what types of treatment one would 
or would not want should one be unable to speak for itself. 
A systematic review on the emotional impact of discussions about end-of-life decisions 
showed that the patients involved experienced positive benefits from the process (Song, 
2004). Hypothetical benefits of ACP reported in the literature include increased inclusion of 
patient preferences for health care, more informed decision making, decreased pain and 
suffering, reduced costs and use of life-sustaining treatments, and improved patient and 
family satisfaction with care (Royal College of Physician, guideline 2009). 
Another review (Knops et al, 2005) identified three domains of patient concern that are 
relevant for advance care planning conversations: 
 feelings about the disease 
 feelings about suffering 
 feelings about the circumstances of death. 
A literature review (Kaldjian, 2008) reported a list of 6 goals can be used to articulate goal-
oriented frameworks to guide decision-making toward the end-of-life and thereby 
harmonize patients' treatment choices with their values and medical conditions: 
1. be cured 
2. live longer 
3. improve or maintain function/quality of life/ independence  
4. be comfortable 
5. achieve life goals 
6. provide support for family/caregiver.  
Discussions about end-of-life care and end-of-life decision-making involve cognitive and 
particularly affective processes and are often emotionally taxing. How end-of-life 
discussions are delivered and what is discussed can influence patient’s decision-making and 
affective outcomes. 
Although the issue has been increasingly in the public eye, few patients have had these 
discussions with their physician or family; and, even when they have, decisions may not 
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be documented in the patient's record. Without plans, a crisis situation can escalate 
quickly, especially if the patient cannot communicate or if the family's preferences conflict 
with the clinician's ones. In these cases, treatment decisions are not made, they simply  
happen, usually based on habits that are presumed to reflect what patients generally 
want. 
ACP can be difficult, there may be actual barriers (Lynn et al, 2007): 
 Everyone is reluctant to talk about the patient's declining health and approaching 
death. 
 Clinicians find it easier to offer comfort, hope, and medical technology rather than to 
"let people die." 
 Patients and families find it hard to believe that treatments such as resuscitation will 
not restore health. 
 Clinicians and family may not accept the patient's treatment priorities and values. 
Recently the Royal College of Physicians, (2009), has release some Evidence-based 
Guidelines for clinical management, “Advance Care Planning”. In box 3 recommendations 
are reported about the physician approach to ACP: 
 
 Ideally, ACP discussions should be initiated in primary care 
 ACP should be offered during routine clinical practice, but never forced upon 
 Professionals should initiate ACP discussions with patients using their professional 
judgement to gauge the appropriate time 
 The professional should have adequate knowledge about the disease, treatment and 
the particular individual to be able to give the patient all the information needed to 
express their preferences to make the plan 
 Individuals should be encouraged to choose who they would wish to be included in 
the discussion, such as next of kin or future proxy 
Box 3. When and with whom should I be considering ACP discussions? 
In box 4 the recommendations about the better way to conduct a discussion on ACP with 
the patients are reported: 
 ACP discussions need to be skilfully led and should be a process, not a single event or 
a tick box exercise 
 Professionals should ensure that individuals have every opportunity to participate in 
the discussion by treating reversible illness impacting on decision-making, such as 
delirium or sensory impairment, and ensuring that the patient is pain-free, fed, not too 
tired etc 
 ACP discussions should not be continued if they are causing the patient excessive 
distress or anxiety 
 Professionals should take account of the following factors which influence attitudes to 
discussing ACP, and ensure that these factors do not act as artificial barriers: older people, 
the professional's own personal experience and beliefs, the patient's gender, race, culture, 
sexual orientation, religion, beliefs and values, the patient's concerns about euthanasia 
Box 4. Recommendations of the RCP on how to conduct a discussion about ACP with a 
patient. 
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Finally in box 5 it is clearly reported that all the carers must be trained in ACP discussions 
and that it is essential to record the patients statements. 
 
 Health and social care staff should be trained in ACP discussions, especially 
physician, nursing, social workers and other key workers 
 Staff training should be workplace-based, recurrent and led by experts and expert 
patients 
 Physicians should be routinely reminded to offer ACP discussion at an appropriate 
time to their patients 
 ACP should be part of the Quality Outcomes Framework 
 Medical records should contain a specific section for advance statements 
 A register should be created, which stores details about an individual's ACP 
document, and should be readily accessible with the individual's permission 
 ACP documents should be recorded on the electronic patient record (with the 
patient's consent) 
Box 5. Recommendations for training and implementation of ACP 
In general, discussion about advance care planning should focus more on goals of care than 
on specific treatments, and clinicians should be especially careful to respond to the 
emotional content of the discussion (Tulsky, 2005).  
The underlying principle is that the discussion should move back and forth from 
preferences to reasons and values to information and back, ensuring that the patient 
understands the implications of his or her stated preferences and that the doctor 
understands the patients’ values. Although little evidence exists to guide practice, it may be 
more effective for a physician to make a values-based recommendation, rather than offering 
a variety of choices without guidance (Back, 2008). 
5. The evidence based practice in palliative care 
The palliative approach towards the patient in terminal phase requires that all the health 
carers are able to provide a high quality assistance.  
Palliative Medicine, like any other branch of medicine, needs research to switch from a 
medicine based on opinions to a medicine based on scientific evidence. Clinicians should 
make decisions for the individual patient not only under their own experience, but also with 
the guide of the best available evidence. Evidence Based Medicine (EBM), should guide 
one’s clinical decisions based on the efficacy and safety of a particular intervention in a 
specific population. But only few patients have average characteristics. In Palliative Care the 
difficulty with guidance about symptom control often is the paucity of evidence of sufficient 
quality (Bausewein et al, 2011). 
Since the primary studies are rare, clinically heterogeneous, with small sampling and often 
of poor quality, the scientific evidences in palliative care not always can provide elements of 
“best practice” in order to lead the clinic practice. 
The shortage of the research in palliative care is connected to different concurring factors; 
among them there are: 
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 A particular observation/intervention setting: for example the patient residence that 
makes difficult to realize of complex research protocols; 
 The limited survival of the patients, with short observation times; 
 Subjective experience of the patient during the advanced phases of the illness, that 
usually make impossible a preliminary intervention, even more complicated to be 
realized at the end-of-life;  
 The multidisciplinary integration often is problematic; 
 Techniques and assessment tools are not always comparable between countries. 
Anyway, different types of research protocols can be adapted to the specificity and 
limitations of the palliative medicine in Primary Care: 
 Guidelines Implementation and Clinical audit; 
 Descriptive surveys, quantitative researches with valued questionnaires and qualitative 
researches with unstructured interviews; 
 Testing of pharmaceuticals and equipment, specific but not invasive; 
 Descriptive studies, with the method of the Follow-back survey, using as source of 
information the caregivers, etc. 
5.1 Outcome measurement in palliative care  
Outcome measurement has a major role to play in improving the quality, efficiency and 
availability of palliative care (Bausewein et al, 2011):  
 Outcome measurement is a way of measuring changes in a patient’s health (which can 
be attributed to preceding healthcare) over time; 
 It can be used to improve the quality of healthcare services; 
 Outcome measurement can be used for clinical care, audit and research purposes; 
 There is an increasing need for robust outcome measurement in the field of palliative 
care, but this poses particular challenges and requires special consideration with regard 
to patients’ situations at the end-of-life.  
A patient’s experience can be related to physical (e.g., symptoms and functional status), 
psychological (e.g., cognition and emotions), social and cultural (e.g., family and friends, 
organisational and financial), and spiritual (e.g., beliefs, meaning and religion) domains, 
which are all interlinked.  
Palliative care aims to provide holistic care for patients and families and for this reason an 
outcome measure should be a complex one and ideally cover several of these domains, as 
well as aspects of care (NICE, 2011). 
Most outcome measures (questionnaire or scales) cover various domains and dimensions, 
dimensions relate to measurable quantities or particular aspects of a problem:  
for example, the patient, family and carers, or quality of care, as well as physical  
(Fig. 1). 
A large number of outcome measures have been developed to measure specific physical 
dimensions, for example, symptoms such as pain, breathlessness or fatigue (Table 3).  
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Outcome 
measure 
Number of items Completion time Notes 
Palliative care 
Outcome Scale 
(POS) 
10 items on physical 
symptoms emotional, 
psychological and 
spiritual needs, provision 
of information and 
support  
mean time 6.9 min 
(patients) and 5.7 
min (staff) 
scores from 0 (‘no effect’) 
to 4 (‘overwhelming’) , 
staff patient of and carer 
version; widely used 
palliative care measure 
freely available after 
registration 
POS-S Symptom 
list 
10 symptoms  
2 questions about the 
symptom that affected the 
patient the most and that 
has improved the most 
few minutes scores from 0 (‘no effect’) 
to 4 (‘overwhelming’); 
additional symptom 
versions available for 
other conditions (POS-S 
MS, POS-S renal);  
Distress 
Thermometer 
overall distress score 
20 symptoms, 5 items on 
practical problems, 4 on 
family problems, 
5 on emotional problems, 
2 on spiritual concerns 
 
median length of 
time 5 min, with 
75% taking no 
more than 10 min 
distress score 0-10; 
 other items yes/no 
Edmonton 
Symptom 
Assessment Scale 
(ESAS) 
9 symptoms and “other 
problem” 
Approximately  
5 min 
each symptom with NRS 
0-10 developed to 
measure the most 
commonly experienced 
symptoms in cancer 
patients; freely available 
Memorial 
Symptom 
Assessment Scale 
(MSAS) 
14 items  
7 depression 
7 anxiety 
2-6 min developed to assess 
depression and anxiety 
for people with physical 
illness; not freely 
available 
European 
Organization for 
Research and 
Treatment of 
Cancer - EORTC 
QLQ-C30 
 
5 functional scales 
(physical, role, emotional, 
social, and cognitive),  
3 symptom scales(fatigue, 
nausea, vomiting and 
pain), a global health 
status/QoL scale and six 
single items (dyspnoea, 
insomnia, appetite loss, 
constipation, diarrhoea, 
and financial difficulties) 
first assessment 
12 min 
(SD 7.5 min), 
second 
assessment 11 min 
(SD 6.5 min) 
not freely available, 
widely used in cancer 
research; modular 
supplement available for 
a range of malignancies 
(lung, breast, gastric, 
brain etc.) 
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Outcome 
measure 
Number of items Completion time Notes 
EORTC 
 
pain, physical function (3 
items), emotional function 
(2 items), fatigue (2 items),  
QoL(1 item), 
 symptoms (6 items) 
< 20 min not freely available, 
shortened, version of the 
EORTC QLQ-C30 for 
palliative care patients 
Table 3. Examples of multidimensional outcome measures in palliative care (modified from 
Bausewein et al, 2011) 
 
Fig. 1. Domains and dimensions of outocome measures in palliative care  
(Bausewein et al, 2011) 
Psychological symptoms, such as depression or anxiety, are either measured using separate 
scales or are included in the symptoms’ measures. 
5.2 Pain therapy in palliative care 
Daniel is a 48 y.o. male, suffering from malignant melanoma with liver metastases, 
abdominal and thoracic lymph nodes and multiple bone metastases (spinal multidistrict). 
He is receiving 2 cp of 32 mg hydromorphone/day, oral morphine 50 mg every 4-6 hours 
(rescue dose), bisphosphonates I.V. every 28 days (in hospital), laxative and anti-emetic 
therapy. For three days there is an intense nausea due to liver metastases. Daniel is no 
longer able to take oral therapy. His GP would like to change the oral therapy in a 
parenteral route. What are the available evidences to support the clinical decision 
making? 
Palliative care is operationalized through effective management of pain and other 
distressing symptoms, while incorporating psychosocial and spiritual care according to 
patient and family needs, values, beliefs and culture(s). 
Pain is a symptom defined as “An unpleasant sensory and emotional experience associated 
with actual or potential tissue damage, or described in terms of such damage” (IASP,  
1994).  
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For an adeguate estimation of a patient, the Joint Commission Accreditation of healthcare 
Organization Standard Manual declared in 2002 that the fifth “vital sign” to look for is pain. 
Pain has been identified consistently as one of the major problems in end-of-life care.  
Chronic pain, present not along in cancer but also in degenerative diseases, neurological 
disorders, especially in advanced stages and terminal illness, takes on the characteristics of 
global pain, or in other words, of personal suffering, that finds in its etiopathogenesis 
physical reasons as well as psychological and social causes. 
All types of pain (acute, chronic, and cancer pain) are undertreated, and poorly controlled. 
Adequate pain control can be achieved in most patients at the end-of-life by using a 
comprehensive approach that includes analgesics, adjuvants, education, support, and 
monitoring (Emanuel et al, 2011).  
Patients should be asked about pain severity, quality, location, and temporal features, such 
as onset, duration, diurnal variation, or aggravating/relieving factors. They should be 
actively involved in establishing the goals of palliative pain management, along with family 
members. It is essential to explain the origin and the type of pain, the initial management 
plan (including the role of titration), expected adverse effects and how they will be 
managed, how the pain will be monitored (Emanuel et al, 2011). 
5.2.1 Pain classification 
Pain is a subjective experience, influenced by cultural factors, specific situations and other 
psychological variables. The process of pain does not begin with the simple stimulation of 
the receptors. It is influenced by the personality of the patients, the context in which they 
live, the cultural level and the experiences of life.  
As knowledge about pain has advanced, health care professionals have become increasingly 
aware of the need to develop a more mechanism-based approach to pain control. Cancer 
pain is a paradigmatic combination of physical and inflammatory processes, that may result 
from tissue damage and destruction and/or stimulation of nerves by inflammatory 
mediators produced by the tumor and by the body in response to tumors, too. 
Usually pain can be classified as:  
 Nociceptive pain: is caused by the activation of nociceptive nerve fibers by physical 
tissue destruction or by chemical, pressure, or thermal processes; often it is described as 
sharp and stabbing, while the visceral stimulation derived from the receptors present 
on the internal organs, (such as the bladder, intestine, stomach, etc...), is poorly 
localized and may be deaf or cramping.  
 Neuropathic pain: A new definition was suggested by the IASP Neuropathic Pain 
Special Interest Group (NeuPSIG, 2008). This group redefines neuropathic pain as “pain 
caused as a direct consequence of a lesion or condition that affects the somatosensory 
system”. Neuropatic pain is difficult to treat, given the variety of etiologies, mechanical 
causes and symptoms that characterize it, and its impact on different dimensions of 
health. The pain is of different intensity, that rarely reaches high levels but causes 
intense suffering to the patients. It occurs as a continuous pain, throbbing or stabbing, 
with possible hyperalgesia or hypoalgesia, paresthesia, allodynia.  
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 Mixed: both nociceptive and neuropathic pain are common in illnesses like cancer.  
There are several methods to observe pain, based on the patient's ability to define it 
quantitatively. The measurement of pain is a fundamental tool of the assessment and 
strategy of pain management for pain control. Routinely using the analgesic scales and 
keeping records of the results in the patients medical card helps improve the ability of the 
physician to understand the intensity of pain.  
Several instruments are used, some complex, others easier to use in the setting of general 
practice; the two main categories are:  
Intensity scales, such as: 
 Visual Analogical Scale (VAS) is designed to present to the respondent a rating scale 
with minimum constraints. Respondents mark the location on the 0-10 centimeters line 
corresponding to the amount of pain they experienced. VAS data of this type is recorded 
as the number of millimeters from the left of the line within the range 0-10 centimeters. 
 Numerical Rating Scale (NRS) is an instrument that requires the rater to assign the 
rated object that have numerals assigned to them, instruct the patient to choose a 
number from 0 to 10 that best describes their current pain, 0 would mean ‘No pain’ and 
10 would mean ‘Worst possible pain’. 
 Verbal Rating Scales (VRS) uses specific words to numeric pain describe rather than a 
scale. In other words, the person in pain describes the intensity of pain, and how they 
feel.  
 Analogue Chromatic Continuos Scale is based on gradation of colour along the line 
(e.g. pale pink to dark red, for the worst pain) 
An objective assessment of physical functioning constitutes an important part of the 
multidimensional assessment of pain. Terminally ill patients may curtail their physical 
activity because of pain. Physical activity may also be restricted because of fatigue, cachexia, 
and drowsiness, common in end-stage illness, contributing to rapid deconditioning, with 
severe impairments in overall functional status. 
Multidimensional questionnaires (D’Errico & Valori, 2011) are useful for an overall 
objective and subjective assessment, but are less used by general practitioners because, if 
compared with the intensity scales, it means devoting more time to the patients:  
 McGill Pain Questionnaire can be used to evaluate a person experiencing significant 
pain, can be used to monitor the pain over time and to determine the effectiveness of 
any intervention. 
 Memorial Pain Assessment Card: a scale used to assess 32 physical and psychological 
symptoms in three different dimensions: intensity, frequency, and distress. 
 Brief Pain Inventory: provides information on the intensity of pain (the sensory 
dimension) as well as the degree to which pain interferes with function (the reactive 
dimension). 
5.2.2 Principles of pain control 
Pain control is an important aspect of palliative care, in order to improve quality of life. 
Relief of pain should be seen as part of a comprehensive pattern of care encompassing the 
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physical, psychological, social, and spiritual aspects of suffering. The various components 
must be addressed simultaneously. Disease progression may necessitate increased dosing of 
opioids to control pain; this should not be confused with "tolerance." In fact, when a patient 
with previously well controlled pain develops the need for increasing opioid doses to 
achieve comfort, advancing illness is almost always the cause (Emanuel et al, 1999).  
Flexibility is the key to managing cancer pain. As patients vary in diagnosis, stage of 
disease, responses to pain and interventions, and personal preferences, so must pain 
management. The patient should be actively involved in establishing the goals of palliative 
pain management, along with family members (ICSI Guideline, 2009; NCI, 2009). 
The National Cancer Institute (NCI, 2009) emphasizes the patient involvement in 5 
recommendations (ABCDE):  
 Ask about pain regularly. Assess pain and associated symptoms systematically using 
brief assessment tools. Assessment should include discussion about common symptoms 
experienced by cancer patients and how each symptom will be treated; 
 Believe patient and family reports of pain and what relieves the pain (Caveats include 
patients with significant psychological/existential distress and patients with cognitive 
impairment); 
 Choose pain-control options appropriate for the patient, family, and setting; 
 Deliver interventions in a timely, logical, coordinated fashion; 
 Empower patients and their families. Enable patients to control their course as much as 
possible. 
There are many barriers to a good pain management in palliative care (NCI, 2009). They 
include (table 4) discounting a patient's subjective measure of pain, difficulty in assessment 
of the cognitively impaired, myths believed by both practitioners and patients about opioid 
therapy and fears of addiction and hastening death.  
 
Problems related to health care 
professionals 
Problems related to patients 
Inadequate knowledge of pain 
management 
Reluctance to report pain 
Poor assessment of pain Concern about distracting physicians from 
treatment of underlying disease 
Concern about regulation of controlled 
substances 
Fear that pain means disease is worse 
Fear of patient addiction Reluctance to take pain medications 
Concern about side effects of analgesics Fear of addiction or of being thought of as an 
addict. This fear may be more pronounced in 
minority patients. 
Concern about patients becoming 
tolerant to analgesics 
Worries about unmanageable side effects 
such as constipation, nausea, or clouding of 
thought 
 Concern about becoming tolerant to pain 
medications 
Table 4. Barriers to Effective Pain Management (NCI, 2009) 
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5.2.3 Management of pain  
The World Health Organization (WHO, 1996) produced a pain ladder to be used as a guide 
for prescribing analgesics. The severity of pain, assessed by the scales, is classified as mild, 
(range VAS 1-4), moderate (VAS 5-6) and severe (VAS 7-10) (figure 2). Different type of 
analgesics are used, depending on the severity of pain. A telephone survey conducted in 
2003 in 15 European countries and Israel, which involved 4,839 patients, showed that there 
is considerable diversity in the use of analgesics in chronic pain. Countries with greater use 
of NSAIDs were Poland (71%) and Italy (68%). The weak opioids were used by 36-50% of 
responders in Sweden, UK and Norway, and only 5-9% in Israel, Denmark and Italy. Strong 
opioids were almost unused in Italy, Spagna and Switzerland (0-2%), while 12-13% were 
prescribed in the UK and Ireland (Breivik et al, 2006).  
In all three steps it also is possible to use an adjuvant therapy (various drugs, chemotherapy, 
radiotherapy or/and surgery) to strengthen the action of analgesics (figure 2). 
Patients who did not improve their pain should go to the next step of the analgesic ladder. 
The consensus statement from the American Pain Society and American Academy of Pain 
Medicine (1996) states that the undertreatment of pain is unjustified.  
For many people experiencing cancer pain that is expected to continue, opioids should be 
administered on an “around-the-clock” basis, rather than given only when pain becomes 
intense. The “around-the-clock” approach provides a consistent level of the medication in 
the blood, and this helps to provide a fairly consistent level of pain relief, preventing abrupt 
peaks and valleys of pain, with the use of short-acting opioids as supplemental agents for 
Breakthrough pain. Controlled-release formulations can lessen the inconvenience associated 
with “around-the-clock” administration of short-acting opioids. 
 
Fig. 2. Pain ladder proposed by WHO (1996). 
Recently, the usefulness of step 2 of the WHO ladder has been questioned. Two systematic 
reviews (McNicol et al, 2004; Maltoni et al, 2005) raised questions about delayed 
introduction of strong opioids may result in periods of uncontrolled pain. Nowadays, for 
moderate pain, the recommendation is to consider starting with small doses of a strong 
opioid. (Pergolizzi et al, 2008).  
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In table 5, a synopsis of treatment strategies for chronic pain is reported (Emanuel et al, 
2011); strong opioids are the reference analgesics for moderate to severe pain both for 
nociceptive than neuropathic pain. 
 
Type Nociceptive pain Neuropathic pain 
mild moderate to severe mild moderate to severe 
Typical 
Analgesics 
Non-opioids 
+ weak opioids 
Strong opioids Unuseful (?) Strong opioids 
Adjuvant 
Analgesics 
Acetaminophen 
(paracetamol) 
or NSAIDs 
Acetaminophen or 
NSAIDs, 
Radiotherapy, Surgery 
Tricyclic antidepressants Typical 
and atypical anticonvulsants 
Table 5. Analgesic strategies for Chronic Pain (nociceptive or neuropathic). 
5.2.3.1 Non-opioid typical analgesics 
The non-opioid analgesics are both typical or adjuvant analgesics. They include nonsteroidal 
anti-inflammatory drugs (NSAIDs and COXIBs) and acetaminophen, or paracetamol. 
NSAIDs and Paracetamol are recommended for use alone or in combination with opioids 
both as first line therapy (mild pain) or as adjuvant analgesics (moderate to severe pain).  
NSAIDs are a group of organic acids with analgesic, antipyretic and anti-inflammatory 
properties, indicated for rheumatic pain and skeletal muscle inflammation. The effects of 
NSAIDs are related to inhibition of cyclooxygenase (COX-1 and COX-2) enzyme. 
The inhibition of COX-2 determines the analgesic, anti-inflammatory and antipyretic effect 
typical of COXIBs. NSAIDs and COXIBs reduce pain exerting their action primarily at the 
level of noxious stimuli, which elevate the threshold for activation of nerve endings. 
The commonest adverse events with NSAIDs are gastrointestinal (mucosal erosion and 
bleeding) and renal toxicity. 
The analgesic effect of paracetamol is expressed at the central level; its mechanism of action 
is due to inhibition of prostaglandin synthesis in the central nervous system (CNS), but also 
by the activation of serotonergic pathways descendants. It is administered orally, rectally or 
intravenously. Oral solutions are absorbed more quickly than traditional tablets and 
effervescent soluble tablets even better: they contain sodium bicarbonate, the prokinetic 
action of which promotes gastric emptying and the arrival of the drug in the small intestine 
that is home to the main absorption. 
5.2.3.2 Other adjuvant analgesics 
Tricyclic antidepressants (TCAs) may be useful as adjunctive therapy for cancer-related 
neuropathic pain syndromes. TCAs provide pain relief by independently providing 
analgesia specific for neuropathic pain, potentiating the effect of opioids, and improving 
underlying depression and insomnia. 
TCAs (amitriptyline, nortriptyline, and desipramine) are also thought to have an inhibitory 
effect on nociceptive pain , by raising the levels of serotonin and norepinephrine in the CNS 
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by slowing the rate of reuptake by nerve cells. Their analgesic activity seems to be 
independent from their antidepressant effects. Unfortunately, TCAs also block histaminic, 
cholinergic, and alpha1-adrenergic receptor sites, and this lack of selectivity is what 
accounts for the unwanted side effects such as weight gain, dry mouth, constipation, 
drowsiness, and dizziness. 
Several anticonvulsants (valproic acid, carbamazepine, gabapentin, pregabalin, 
clonazepam and others) have a role in the treatment of neuropathic pain. They are 
thought to inhibit seizures by multiple mechanisms, including functional blockade of 
voltage-gated sodium channels, functional blockade of voltage-gated calcium channels, 
direct or indirect enhancement of inhibitory GABAergic neurotransmission, and 
inhibition of glutamatergic neurotransmission. The effects on neuropathic pain, 
characterized by neuronal hyperexcitability, are probably mediated by the same 
molecular mechanisms. Their efficacy is quite variable; antidepressants and 
anticonvulsants may occasionally be prescribed simultaneously, but it is good clinical 
practice to introduce only one drug at a time. 
5.2.3.3 Opioid analgesics (weaks and strongs) 
The most effective analgesics are the opioid analgesics. The opioids include all drugs that 
interact with opioid receptors in the nervous system. Opioid receptors are a group of G 
protein-coupled receptors with opioids as ligands. These receptors are the sites of action for 
the endorphins, compounds that already exist in the body and are chemically related to the 
opioid drugs that are prescribed for pain. Most opioids undergo biotransformation in the 
liver and are primarily eliminated by kidneys as a mixture of the parent opioid and their 
metabolites. Accumulation of active metabolites with analgesic or neurotoxic effects can 
result in significant toxicity. 
 
WEAK OPIOIDS 
AGONISTS PARTIAL AGONISTS 
Codeine 
Propoxyphene 
Hydrocodone 
Dihydrocodeine 
Tramadol 
Buprenorphine 
STRONG OPIOIDS 
AGONISTS AGONISTS/ANTAGONISTS 
Morphine 
Oxycodone 
Hydromorphone 
Methadone 
Fentanyl 
Diamorphine 
Oxymorphone 
Meperidine 
Levorphanol 
Sufentanil 
Alfentanil 
 
Pentazocine 
Butorphanol 
Nalbuphine 
Table 6. Classification of Opioid Analgesics by Receptor Interactions (modified from 
Emanuel et al, 2011) 
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Opioid metabolism knowledge helps in initial selection and titrating the dose in terminally 
ill patients. On the basis of the interactions with the various CNS receptor subtypes (mu, 
kappa, and delta) the opioids can be divided into pure agonists, partial agonists, mixed 
agonists and antagonists (Table 6). The latter two groups are generally not useful in terminal 
illness, because of partial or total “ceiling effect” (the effect is not dose-dependent) for 
analgesia and undesired dysesthesia for the activation of K-receptors associated with some 
agents.  
The EAPC survey in 42 European countries (EAPC survey, 2006) showed that the most 
frequently used opioid (68%) is morphine (see also table 1). Morphine is referred to as the 
"gold standard" for pain treatment in palliative care, because it is effective, inexpensive and 
easy-to-holder. In other countries (18%), such as Italy, Spain, Luxemburg, Austria and 
Belgium, the most widely used opioid was fentanyl, a strong one, but quite expensive and 
difficult to titrate. Tramadol, a weak opioid, was the first used in 8% of the other countries. 
Morphine is the first-choice strong opioid in palliative care, because it is very effective, 
inexpensive, and easy to titrate. It can administered using many routes including oral, rectal, 
parenteral, subcutaneous and spinal route. Morphine binds to opioid receptors in the CNS, 
reducing the perception as well as the emotional response to pain. Alternative opioids have 
not demonstrated advantages that would make them preferable as first-line drugs for cancer 
pain. Over the past decade very few new opioids have been developed, but rather new 
formulations have been made (oral controlled-release formulations, transdermal patches, 
oral transmucosal devices, buccal adhesive tablets, nasal sprays) to optimise their overall 
use and to increase usage especially for malignant pain (Janet et al, 2009). 
Oxycodone is a strong opioid, used to treat moderate to severe pain. The extended-release 
form of this medication is for “around-the-clock” treatment of pain. In case of insufficient 
analgesia and/or intense adverse effects such as sedation, hallucinations and nausea and 
vomiting a switch from another opioid to oxycodone might be beneficial. Oxycodone is 
mainly used as controlled-release tablets for chronic pain. The immediate-release solution 
and tablets are used for acute pain or for BTcP. Parenteral oxycodone is a good alternative 
when opioids cannot be administered orally (Biancofiore, 2006). 
Hydromorphone, is a semi-synthetic morphine derivative that differs slight from morphine 
in its chemical structure: this makes it 5–10 times more potent and enhances its distribution 
into the brain making titration of the effects easier. Hydromorphone may be better tolerated 
than morphine in patients with renal failure (Felden et al, 2011). 
Fentanyl is an agonist strong opioid analgesic, effective for the treatment of acute and 
chronic pain via multiple routes of administration:  
 Transdermal fentanyl (Transdermal System – TDS or Patch) releases the opioid for three 
days, needle-free, easy to use and circumventing barriers to the use of oral analgesics, 
for example in patients with nausea. The main problem is the dose titration to obtain 
pain-control: the patch should be introduced only when the pain is under control with 
an oral opioid.  
 Oral transmucosal fentanyl citrate (OTFC), the so-called lollipop, utilizes the rapid 
uptake through the buccal mucosa to achieve high plasma concentrations rapidly; the 
OTFC is indicated to treat Break-Through cancer Pain (BTcP).  
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 The fentanyl buccal tablets (FBT) offer slightly better pharmacokinetics for the same 
indication, as Fentanyl buccal soluble film (FBSF), a small, bilayered, water-soluble 
polymer film that adheres to the buccal mucosa and rapidly delivers fentanyl into the 
systemic circulation. 
 The intranasal fentanyl spray (INFS) route is another option to achieve rapid uptake of 
fentanyl, indicated to treat acute and BTcP relief (Grape et al, 2010). 
Despite the current availability of alternatives to morphine, the recommendations of the 
European Association for Palliative Care (Hanks et al, 2001) on the use of opioids in cancer 
pain remain still valid. However, most of the recommendations are not based on strong 
scientific evidence but on the clinical experience of respected authorities from expert 
committees. Table 7 describes some of the key recommendations. 
Grading*  
C The opioid of first choice for moderate to severe cancer pain is morphine. 
C If patients are unable to take morphine orally the preferred alternative route is 
subcutaneous There is generally no indication for giving morphine 
intramuscularly for chronic cancer pain because subcutaneous administration is 
simpler and less painful. 
C The optimal route of administration of morphine is by mouth. Ideally, two types 
of formulation are required: normal release (for dose titration) and modified 
release (for maintenance treatment). 
A Oral transmucosal fentanyl citrate (OTFC) is an effective treatment for ‘BTcP’ in 
patients stabilized on regular oral morphine or an alternative step 3 opioid.  
A Hydromorphone or oxycodone, if available in both normal release and modified 
release formulations for oral administration, are effective alternatives to oral 
morphine.  
B Transdermal fentanyl is an effective alternative to oral morphine but is best 
reserved for patients whose opioid requirements are stable. 
C Methadone is an effective alternative, but may be more complicated to use 
compared with other opioids because of pronounced interindividual differences 
in its plasma half-life, relative analgesic potency and duration of action. 
B Spinal (epidural or intrathecal) administration of opioid analgesics in 
combination with local anaesthetics or clonidine should be considered in 
patients who derive inadequate analgesia or suffer intolerable adverse effects 
despite the optimal use of systemic opioids and non-opioids. 
*The grading system express the robustness of scientific evidence: an A recommendation is sustained 
by a strong scientific proofs, while a D evidence is mainly based on expert-opinion. Grade B and C 
express intermediate levels of evidence.  
Table 7. Recommendations about the use of Morphine and alternative opioids in cancer pain 
(Hanks et al, 2001) 
Decision pathway to manage pain in terminally ill patients involves selecting the right 
opioid at the right dose, frequency, and route, and the prevention and treatment of opioid 
side effects. Careful opioid titrations with close monitoring of outcomes (eg. pain relief, side 
effects, physical aid psychosocial functioning) is required to achieve an individualized 
analgesic response.  
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 give in adequate dosage  
 titrate the dose for each individual patient  
 schedule administration according to drug pharmacology  
 administer on a strict schedule to prevent pain  
 give written instructions for patients on multiple drugs  
 give instructions for treatment of Breakthrough pain  
 warn of, and give treatment to prevent, adverse effects  
 keep the analgesic program as simple as possible  
 use the oral route wherever possible  
 review and reassess 
Box 6. Principles of analgesic administration (modified from Doyle & Woodruff, 2008) 
The principles of analgesic administration (particularly for opioid analgesics) in the 
treatment of chronic pain are summarized in box 6 (Doyle & Woodruff, 2008). 
A decision pathway algorithm for opioid therapy (Eti & Heidelbaug, 2011) is reported in 
Figure 2. 
Opioid rotation, especially for patients with cancer, should be considered when opioid side 
effects are difficult to manage. This approach is based on the clinical observation that 
intraindividual response varies remarkably from opioid to opioid and that a change to an 
alternative drug may yield a far better balance between analgesia and side effects. The 
opioid rotation/switching/ substitution is a strategy that includes:  
 changing to a different medication by using the same route of administration, or 
 maintaining the current medication, but changing the route of administration, or 
 changing both the medication and the route of administration,  
because of insufficient pain management, intolerable adverse effects, need for change the 
administration route and economics.  
When opioid rotation is applied in the setting of unacceptable adverse effects, the selection 
of an alternative opioid is largely empiric. A pure opioid agonist is recommended. Opioid 
rotation has been shown to be useful in opening the therapeutic window and establishing a 
more advantageous analgesia/toxicity relation (Vadalouca et al, 2008). 
Many patients develop adverse effects such as constipation, nausea, vomiting, urinary 
retention, pruritus and CNS toxicity (drowsiness, cognitive impairment, confusion, 
hallucinations, myoclonic jerks and—rarely—opioid-induced hyperalgesia/allodynia). In 
some cases a reduction in opioid dose may alleviate refractory side-effects. This may be 
achieved by using a co-analgesic or an alternative approach such as a nerve block or 
radiotherapy (adjuvant therapy). Other strategies include the continuous use of antiemetics 
for nausea, laxatives for constipation, antipsychotics for confusion and delirium and 
psychostimulants for drowsiness. However, since some of the side-effects may be caused by 
accumulation of toxic metabolites, switching to another opioid agonist and/or another route 
may allow titration to adequate analgesia without the same disabling effects. This is 
especially true for symptoms of CNS toxicity like opioid-induced hyperalgesia/allodynia 
and myoclonic jerks (Jost & Roila, 2010).  
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Fig. 3. Pathway algorithm for opioid therapy (from Eti & Heidelbaug, 2011) 
Disadvantages of opioid rotation include problems related to inaccurate conversion of the 
doses, limited availability of certain opioid formulations, drug interactions, and the 
possibility of increased expense. Weighing the advantages and disadvantages is essential 
prior to making a decision about opioid rotation selection. This approach requires 
familiarity with equianalgesic doses of the different opioids (see Table 8). 
5.2.4 The Breakthrough (cancer) Pain (BTcP) 
Breakthrough (cancer) pain (BTcP) is a common problem in patients with cancer, associated 
with significant morbidity in this group of patients (Davies, 2006). The original definition of 
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BTcP was “a transitory exacerbation of pain that occurs on a background of otherwise stable 
pain in a patient receiving chronic opioid therapy”(Portenoy,1990).  
It appears within a few minutes and lasts about 30-45 minutes, distinctly different from the 
basic pain, with which it shares the location and irradiation. 
A newer version has suggested an extension of the definition of BTcP: “a transient 
exacerbation of pain that occurs either spontaneously, or in relation to a specific predictable 
Drug Oral  
Route 
Parenteral 
Route 
Conversion Ratio to 30mg Oral Morphine (OM) 
Morphine 
sulfate 
30mg  10mg  Parenteral morphine is 3 times as potent as OM 
Oxycodone 20mg  NA Oral Oxycodone is roughly 1.5 times more potent 
than OM 
Hydrocodone 20mg  NA Oral hydrocodone is roughly 1.5 times more 
potent than OM 
Hydromorphone 6 mg  1.5 mg  Oral hydromorphone is about 5 times as potent as 
OM 
Parenteral hydromorphone is 20 times as potent 
as OM 
Fentanyl TDS NA 12-15 
mcg/hr  
TDS 
TDS fentanyl is approximately 80 times as potent 
as OM 
Table 8. Opioid Equivalency – Strong Opioid (daily doses) 
or unpredictable trigger, despite relatively stable and adequately controlled background 
pain”(Davies, 2009). The characteristics of pain are: 
 High intensity 
 Frequent involvement of the same basic site of pain 
 Acute clinical manifestation  
 Appearance during the day that is repeated with variable frequency 
BTcP can place a significant physical, psychological and economic burden on patients. 
Despite advances in the management of cancer pain, through the application of modern, 
evidence-based, multimodality management and the availability of new treatment options, 
recent European surveys have indicated that the diagnosis and treatment of BTcP is still 
suboptimal. A general lack of consensus on its definition alongside poor recognition and 
inadequate assessment may often lead to under-treatment and poor patient outcomes 
(Dickman, 2011). 
A task group of the Science Committee of the Association for Palliative Medicine of Great 
Britain and Ireland (APM, 2009) has produced some up-to-date, evidence-based, practical, 
clinical guidelines on the management of BTcP in adults. The task group was unable to 
make recommendations about any individual interventions for the lack of strong evidences; 
however the group released 12 recommendations about certain generic strategies (Table 9), 
based on limited evidence (i.e., case series, expert opinion). 
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Grading*   
D Patients with pain should be assessed for the presence of BTcP. 
D Patients with BTcP should have this pain specifically assessed. 
D The management of BTcP should be individualized. 
D Consideration should be given to treatment of the underlying cause of the 
pain. 
D Consideration should be given to avoidance/treatment of the precipitating 
factors of the pain. 
D Consideration should be given to modification of the background analgesic 
regimen /“around the clock medication”. 
D Modification of the background analgesic regimen has been shown to be a 
useful approach in managing BTcP, and may involve one or more of the 
following treatment strategies:  
 Titration of opioid analgesics. Titrating the opioid can be effective in 
reducing the intensity and/or frequency of movement-related 
volitional incident pain (Mercadante et al, 2004). However, his 
strategy is often limited by the existence/development of dose-
dependent adverse effects (e.g., sedation) (Portenoy, 1997). 
 Switching of opioid analgesics. Switching the opioid and/or the 
route of administration of the opioid can also be effective in 
reducing the severity of movement-related volitional incident pain 
(Kalso et al, 1996; Enting et al, 2002). 
 Addition of ‘‘adjuvant analgesics”. Adjuvant analgesics (‘‘co-
analgesics”) are agents whose primary function is not analgesia, but 
which provide pain relief in certain circumstances (Lussier & 
Portenoy, 2004). This strategy can be effective in reducing the 
impact of specific BTcP syndromes (e.g., antiepileptics for 
neuropathic pain, anti-spasmodics for visceral pain) (Gannon & 
Davies, 2006). 
 Addition of other ‘‘adjuvant drugs”. Adjuvant drugs are agents 
whose function is not analgesia, but which provide relief from the 
adverse effects of analgesic drugs (or the complications of the pain) 
(Lussier & Portenoy, 2004). This strategy can be effective in allowing 
titration of the analgesic drugs, which in turn can be effective in 
reducing the impact of BTcP (e.g., psychostimulants for opioid-
related sedation) (Bruera et al, 1992). 
 Other strategies. In theory, alteration and/or addition of non-opioid 
analgesic drugs could also lead to improvements in BTcP (e.g., 
paracetamol, non-steroidal anti-inflammatory drugs) (Gannon & 
Davies, 2006). 
D Opioids are the “rescue medication” of choice in the management of BTcP 
episodes. 
B The dose of opioid “rescue medication” should be determined by individual 
titration. 
D Non-pharmacological methods may be useful in the management of BTcP 
episodes. 
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Grading*   
D Non-opioid analgesics may be useful in the management of BTcP episodes. 
D Interventional techniques may be useful in the management of BTcP. 
D Patients with BTcP should have this pain specifically re-assessed. 
*The grading system express the robustness of scientific evidence: an A recommendation is sustained 
by a strong scientific proofs, while a D evidence is mainly based on expert-opinion. Grade B and C 
express intermediate levels of evidence.  
Table 9. Recommendations for the management of BTcP (Davies et al, 2009) 
5.2.5 Constipation and opioid therapy 
Side effects are a common and predictable consequence of the opioid therapy; they may 
either occur acutely and suddenly or as a consequence of a long-term therapy. The most 
common side effects are constipation, drowsiness, nausea, pruritus and confusion.  
Constipation is one of the most common problems experienced by patients in palliative care, 
particularly those with advanced cancer. The rate of patients with terminal disease affected 
by constipation varies from 23% to 87% (Librach, 2010; Noguera, 2009; Larkin, 2008; 
Lagman, 2005), with the highest incidence observed in patients treated with opioids 
(prevalence 50-95% in several studies: Clark, 2010; Noguera, 2009; Woolery, 2008; Lagman, 
2005). Among opioid-treated cancer patients constipation can cause extreme suffering and 
discomfort. Despite these data, constipation is often undervalued by all the care providers, 
since it is considered a minor symptom. 
Patients’ assessement for constipation symptoms should be done at every office visit and a 
stimulant-based bowel regimen at the beginning of chronic opioid therapy should be 
routinely initiate. Recommendations (Larkin, 2008; VaDoD, 2010) for the farmacologic 
treatment of constipation in palliative care patients are listed below:  
 Initial bowel regimens should generally consist of a bowel stimulant and a stool 
softener as well as general measures, such as increased fluid intake, increased dietary 
fiber, and adequate exercise. 
 If inadequate, mild hyperosmotic, saline, and emollient laxatives may be added. 
 If possible, reduce or discontinue other drugs that may cause or contribute to 
constipation. 
 Bulk-producing laxatives, such as psyllium and polycarbophil, are not recommended 
and are relatively contraindicated as they may exacerbate constipation and lead to 
intestinal obstruction in patients with poor fluid intake. 
A revision of clinical guidelines identified only two documents on the management of 
opioid-induced constipation in palliative care patients (Woolery M, 2008; Librach S. L, 2010); 
the recommendations are mainly based on expert-opinions: 
 Opioids should not be reduced during the treatment of constipation unless it is 
absolutely necessary (Librach S. L, 2010); 
 Switching opioids such as morphine slow-release oral to transdermal fentanyl may 
decrease constipation (Woolery M, 2008); 
 Replace the opioid methadone can lead to a reduction in the consumption of laxatives 
(Woolery M, 2008); 
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 Methylnaltrexone is recommended, as an option, to patients treated with opioids that 
do not respond to usual laxative therapy (Librach S. L, 2010) 
Methylnaltrexone (MNTX) is only registered for use in palliative care patients with opioid-
induced constipation who did not responde to adequately titrated laxatives, and in whom 
bowel obstruction has been excluded. MNTX is not a treatment for constipation caused by 
factors other than opioids. MNTX is an opioid antagonist that, in clinical doses, is unable to 
cross the blood–brain barrier. Therefore, it can reverse the effect of opioids in the peripheral 
nervous system and relieve constipation (response of about 50% to laxation after 1 or more 
doses are given) without reversing the analgesic effect of opioids in CNS (Nerissa & 
Baumrucker, 2011).  
6. Conclusions  
Palliative care is a holistic, patient-centered, and culturally sensitive approach to care. To 
have a meaningful effect on patients’ quality of life and end-of-life care, palliative care 
services should be provided earlier in the course of the disease. However palliative care 
reach the maximum impact if it can establish a good communication and a respectful 
relationship with both the patient and his/her carers. Giving dignity, space and attention to 
the communication are essential steps that need to be undertaken by a doctor that 
recognizes a correct relationship with the patient as one of his main means of cure and 
essential for a better Advance Care Planning (ACP).  
The essence of the doctor–patient relationship makes family physicians ideally suited to 
provide home end-of-life care. A good primary palliative care is essential, as it allows 
patients to remain at home as long as they desire. Many patients want to be informed about 
their diagnosis, prognosis, treatments and related side effects, even though they are “bad 
news”.  
Stimulate and record ACP at an appropriate time is a good clinical practice in palliative care. 
All the carers should receive an adequate training in ACP discussions with terminally-ill 
patients. ACP statements should be recorded in medical documents and readily accessible 
to all the care staff . 
The role of Evidence Based Medicine (EBM) in palliative care is limited, since the scientific 
evidences not always can provide elements of “best practice” in order to lead the clinic 
practice. However EBM can be useful to handle some situations, such as the treatment of pain 
and other common symptoms in palliative care. Pain has been identified consistently as one of 
the major problems in end-of-life care. All types of pain (acute, chronic, and cancer pain) are 
undertreated and poorly controlled. To obtain effective results in the pain treatment the 
patient should be fully informed on the origin and type of pain and how it will be monitored; 
the patient should also be involved in the management plan (including the role of opioid 
titration) and in the treatment of the expected adverse effects (e.g. the constipation). 
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